Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists - Wikidata - wikimedia - TriplyDB

Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists

Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists

http://www.wikidata.org/entity/Q42283741

about

New combination treatments in the management of asthma: focus on fluticasone/vilanterol COPD: maximization of bronchodilation.Pharmacotherapy of critical asthma syndrome: current and emerging therapies.Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.The acute management of asthma.On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor.Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands.Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands.Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization G Protein-Coupled Receptor Endocytosis Confers Uniformity in Responses to Chemically Distinct Ligands.Micro-pharmacokinetics: Quantifying local drug concentration at live cell membranes.Characterization of Kinetic Binding Properties of Unlabeled Ligands via a Preincubation Endpoint Binding Approach.Detection and pharmacokinetics of salmeterol in thoroughbred horses following inhaled administration.

P2860

Q26852898-ED94B9CC-DD55-4641-8783-94C22E7514E4 Q34436393-B23CF8DD-F738-4FB7-8079-C719B4AEF4CF Q38157770-4E4262F2-3975-4E0C-9E90-88B3E3F9F217 Q38241442-909ED390-1A88-4038-891C-FC4AB592004A Q38248502-4E5912B3-D40E-49FF-934E-3F0C74962D32 Q38545579-9087B497-D017-48DF-AC31-33DE1F4E33A8 Q38803217-24D16CD3-F682-4682-A2F5-678C52925696 Q38822818-C2CEDD12-C246-46B2-86D4-4D3341139996 Q39116722-2CDB35AB-E27C-4F23-AE4B-ABB5F34C0220 Q41449385-F79251AE-0BD6-4A2A-B3C0-84658BC03FBE Q41895360-07A8857D-CDE6-467C-BBA0-6E01CA5C40AF Q42249769-AAFAE6EF-C8EA-4A0F-87CA-DEA6E1BC7D7F Q46308914-894844FB-CFFA-4293-B0EE-1C537227B900 Q50330984-7BCFA244-307C-4981-AEAC-6D31176D51B6 Q50632046-7742082E-2843-4B0D-9012-60728198AAB9 Q50948358-DFAE4078-AE87-4FFF-8A13-404B3190EA75

P2860

Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists

http://www.wikidata.org/entity/Q42283741

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Slow receptor dissociation is ...... cting β2-adrenoceptor agonists

@en

Slow receptor dissociation is ...... cting β2-adrenoceptor agonists

@nl

type

label

Slow receptor dissociation is ...... cting β2-adrenoceptor agonists

@en

Slow receptor dissociation is ...... cting β2-adrenoceptor agonists

@nl

prefLabel

Slow receptor dissociation is ...... cting β2-adrenoceptor agonists

@en

Slow receptor dissociation is ...... cting β2-adrenoceptor agonists

@nl

P1433

Q42283741-30694AB8-AE90-4ABD-B439-A7CDB505C653

P1476

Q42283741-B42574E2-78B1-4A14-AFBC-DAF852D51A6E

P2093

Q42283741-09D5093C-6035-4B1E-BF13-96E75CA5E683

Q42283741-C18AA8BB-101C-489A-B87E-F910492AE83A

P2860

Q42283741-0287ECB2-0E31-4D8C-A3A1-ED3CD152ED1B

Q42283741-0B9B98B0-6B11-4583-AB55-25364F28B4DA

Q42283741-129920B7-217A-4ABB-8934-F2649842FA23

Q42283741-1D34C85E-3254-4AD6-890A-7613037A7334

Q42283741-1D865F56-67A5-45C8-AFE2-56B6D1FDCD7C

Q42283741-2123258A-EA65-40A5-B181-1077BC92993F

Q42283741-3A5A2DC9-1C59-4AE3-A3CB-F0BE58CEBB71

Q42283741-3FF9E7AF-9D47-43A1-AF0C-B92B358DFA32

Q42283741-47A59418-38F1-4868-92EC-CD0EB25B2FA7

Q42283741-49743CDF-46A8-4187-B3F0-2339D2694708

P304

Q42283741-0B9D55B2-E1DE-4A18-B071-F054474EB42A

P31

Q42283741-B6698E02-11FE-4D0D-AD41-482529463B73

P356

Q42283741-B84CED79-C19D-4196-A62D-F11836B96BAE

P407

Q42283741-69EF2C64-1225-4B3F-A70C-9C1C843266C5

P433

Q42283741-2D3C8ABD-4B2B-43E9-B412-6F21FFF3D317

P478

Q42283741-C598E711-47E9-45F2-9419-6E8A795B2AEF

P50

Q42283741-74D7141A-4C80-40CB-9C49-550EA09F982C

Q42283741-DF59FE76-DFEE-40C6-9B5C-77D3F4D7FF97

P577

Q42283741-62C75DF6-3C5E-49F4-A43B-BC54493C87FA

P5875

Q42283741-77805EFA-4998-4D96-AF51-02FAEB152327

P698

Q42283741-76E917D6-C8F0-4A08-8ABA-1781E0A52A18

P921

Q42283741-7763AC99-DC56-471E-876F-38D02322582F

P932

Q42283741-3ABFCF59-1DEC-493B-AB6B-B6AB6A045896

P356

J.1476-5381.2011.01639.X

P1433

British Journal of Pharmacology

P1476

Slow receptor dissociation is ...... cting β2-adrenoceptor agonists

@en

P2093

David A Sykes

http://www.w3.org/2001/XMLSchema#string

Steven J Charlton

http://www.w3.org/2001/XMLSchema#string

P2860

Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers

Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase.

Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease.

A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.

Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.

Why are long-acting beta-adrenoceptor agonists long-acting?

Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.

P304

2672-2683

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1476-5381.2011.01639.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P50

Steven J. Charlton

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51611679

http://www.w3.org/2001/XMLSchema#string

P698

21883146

http://www.w3.org/2001/XMLSchema#string

P921

P932

3423252

http://www.w3.org/2001/XMLSchema#string